NCT05124717View on ClinicalTrials.gov

Fed Bioequivalence Study of 2 Metformin 500 mg Prolongued Release Tablets in 28 Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

July 3, 2019

Study Completion Date

July 3, 2019

Conditions

Pharmacokinetics

Interventions

DRUG

Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)

One tablet of the Test product was administered orally with 240 mL of water.

DRUG

Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)

One tablet of the Reference product was administered orallyn with 240 mL of water.

Trial Locations (1)

10200

QUINTA-ANALYTICA s.r.o., Prague

All Listed Sponsors

lead

"Joint Stock Company Farmak"

INDUSTRY

NCT05124717 - Fed Bioequivalence Study of 2 Metformin 500 mg Prolongued Release Tablets in 28 Healthy Male and Female Volunteers | Biotech Hunter | Biotech Hunter